Home › Caris, Threshold Pharmaceuticals to Develop Cancer Drug Response Assay

Caris, Threshold Pharmaceuticals to Develop Cancer Drug Response Assay

Oct 25, 2016

NEW YORK (GenomeWeb) – Caris Life Sciences and Threshold Pharmaceuticals announced today that they have partnered to develop a tissue-based assay to predict how pancreatic cancer patients will respond to Threshold’s investigational drug evofosfamide.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Featured Webinar

A Long-Read vs. Short-Read Platform Comparison: Best NGS approaches for Microbiome Studies

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

What's Popular?

In Cancer

  1. Cancer Genetics Cancels Planned Merger With NovellusDx

  2. Guardant Health to Develop Blood-Based CDx for AstraZeneca Drugs

  3. Black Women With Breast Cancer Fare Worse, TAILORx Analysis Confirms at SABCS

    Premium

  4. Synlab Pharma, Biotype Collaborate on Gastrointestinal, Endometrial Cancers

  5. Guardant Health to Launch Cell-Free DNA Assay for Cancer Recurrence Monitoring in 2019

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.